Figure 2. Proliferation of RT112^par and RT112^res.

Temsirolimus-resistant cells were exposed to temsirolimus [1 μmol/ml] three times a week. Tumor cells were further treated with VPA [1 mmol/ml] in the BrdU assay for 24 h or 48 h. Controls remained untreated. (A) BrdU incorporation [RFU] for each sample. (B) % difference of VPA treated cells to controls without VPA. Bars indicate standard deviation (SD). ^*indicates significant difference to control, ^#indicates significant difference to parental cells, p ≤ 0.05. n = 5.